Quick Answer
aTYR PHARMA INC reported Operating Income Loss of -$77.63 million for the year ending 2025.
- aTYR PHARMA INC showed a decrease of -14.3% in Operating Income Loss from 2024 to 2025.
- This data is from aTYR PHARMA INC's annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$5.93 million | Q2 2014: -$5.36 million | Q3 2014: -$6.23 million | Q1 2015: -$8.92 million | Q2 2015: -$10.90 million | Q3 2015: -$11.31 million | Q1 2016: -$16.12 million | Q2 2016: -$15.43 million | Q3 2016: -$13.87 million | Q1 2017: -$13.21 million | Q2 2017: -$11.91 million | Q3 2017: -$10.83 million | Q1 2018: -$10.22 million | Q2 2018: -$9.96 million | Q3 2018: -$6.68 million | Q1 2019: -$5.88 million | Q2 2019: -$5.64 million | Q3 2019: -$5.50 million | Q1 2020: $1.86 million | Q2 2020: -$6.32 million | Q3 2020: -$6.51 million | Q1 2021: -$7.20 million | Q2 2021: -$10.45 million | Q3 2021: -$7.73 million | Q1 2022: -$12.38 million | Q2 2022: -$12.58 million | Q3 2022: -$13.49 million | Q1 2023: -$12.79 million | Q2 2023: -$13.56 million | Q3 2023: -$12.62 million | Q1 2024: -$16.64 million | Q2 2024: -$17.32 million | Q3 2024: -$18.14 million | Q1 2025: -$15.77 million | Q2 2025: -$20.31 million | Q3 2025: -$26.75 million.
- Over the full 13 years of available data (2013 to 2025), aTYR PHARMA INC's Operating Income Loss has declined by 297.2%.
- Historical annual values: Fiscal year 2025: -$77.63 million | Fiscal year 2024: -$67.91 million | Fiscal year 2023: -$54.92 million | Fiscal year 2022: -$46.40 million | Fiscal year 2021: -$34.02 million | Fiscal year 2020: -$15.91 million | Fiscal year 2019: -$22.98 million | Fiscal year 2018: -$32.82 million | Fiscal year 2017: -$47.15 million | Fiscal year 2016: -$57.94 million | Fiscal year 2015: -$47.62 million | Fiscal year 2014: -$23.55 million | Fiscal year 2013: -$19.54 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: